ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ¿¹Ãø - Á¦Ç°º°, Á¦Çüº°, À¯Çüº°, À¯Åë ä³Îº° Áö¿ª ºÐ¼®(-2031³â)
North America Dry Eye Products Market Forecast to 2031 - Regional Analysis - by Product, Dosage Form, Type, and Distribution Channel
ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº 2023³â¿¡ 38¾ï 2,536¸¸ ´Þ·¯¿¡ ´ÞÇßÀ¸¸ç, 2031³â±îÁö´Â 55¾ï 8,777¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2023³âºÎÅÍ 2031³â±îÁöÀÇ CAGRÀº 4.9%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾È±¸°ÇÁ¶ÁõÀÇ À¯º´·ü »ó½ÂÀÌ ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀ» µÞ¹Þħ
¾È±¸°ÇÁ¶Áõ(DED)Àº ¾È°ú Ŭ¸®´ÐÀ» ÁøÂûÇÏ´Â °¡Àå ÀϹÝÀûÀÎ ÀÌÀ¯ Áß¿¡¼ ±¼Àý ÀÌ»ó, ¹é³»Àå¿¡ À̾î 3À§¿¡ ·©Å©µÇ°í ÀÖ½À´Ï´Ù. °ÇÁ¶ÇÑ ´«ÀÇ À¯º´·üÀº ¼±Áø±¹¿¡¼ ƯÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °ÇÁ¶ÇÑ ´«Àº ºÒÄè°¨, ÀÚ±Ø ¹× ½Ã°¢ Àå¾Ö¸¦ ÃÊ·¡ÇÏ´Â ¿©·¯ ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ¹Ì±¹ ¾È°úÇÐȸ°¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é DED´Â ¼¼°è ¾à 11¸í Áß 1¸íÀÌ ÀÌȯµÇ°í ÀÖÀ¸¸ç, ±× À¯º´·üÀº ´Ù¾çÇÑ ¿¬·ÉÃþ¿¡¼ 5%¿¡¼ 50%¿¡ À̸¥´Ù°í ÇÕ´Ï´Ù. 2022³â AlconÀÇ º¸µµ ÀÚ·á¿¡ µû¸£¸é, ÀÌ Áúº´Àº ¼¼°è¿¡¼ 7¾ï 1,900¸¸ ¸í, ¹Ì±¹¿¡¼ ¾à 3,800¸¸ ¸íÀÌ ¾Î°í ÀÖ½À´Ï´Ù.
´ç´¢º´ ¸Á¸·Áõ¿¡ ÀÇÇØ ¸Á¸·¿¡ ¹ß»ýÇÏ´Â ÁøÇ༺ Àå¾Ö´Â Ãß°¡·Î DED¸¦ À¯¹ßÇÕ´Ï´Ù. ¹Ì±¹ ¾È°úÇÐȸ(American Academy of Ophthalmology)°¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é 2030³â±îÁö Àü ¼¼°è¿¡¼ 1¾ï 9,100¸¸ ¸íÀÌ ´ç´¢º´ ¸Á¸·Áõ¿¡ °É¸° °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´ ¿¹¹æ°ü¸®¼¾ÅÍ(CDC)¿¡ µû¸£¸é ¹Ì±¹¿¡¼´Â 2021³â¿¡ ¾à 960¸¸ ¸í(Àü¿¬·ÉÃþ)ÀÌ ´ç´¢º´ ¸Á¸·ÁõÀ» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ ´ç´¢º´¼º ¸Á¸·ÁõÀÇ ÀÌȯÀ² Áõ°¡´Â ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
ºÏ¹Ì ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå °³¿ä
ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀå ¹è°æÀ¸·Î´Â ¾È±¸°ÇÁ¶Áõ(DED)¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í, ³ëÈ Àα¸ Áõ°¡, ±â¼ú Áøº¸, ¾ÈÁúȯ ȯÀÚ Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ½Å¾àÀÇ ºó¹øÇÑ Ãâ½Ã·Î ´Ù¾çÇÑ ¾àÁ¦¸¦ ½±°Ô ÀÔ¼öÇÒ ¼ö ÀÖ´Â °Íµµ ÀÌ Áö¿ªÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.
DED´Â ¹Ì±¹¿¡¼´Â ÈçÇÑ Áúº´ÀÌÁö¸¸, Àß Áø´ÜµÇÁö ¾Ê¾ÒÀ¸¸ç Àα¸ ¿¬·É Áõ°¡°¡ ÀÌ Áúº´ À¯º´·üÀÇ ±ÞÁõ°ú °ü·ÃµÉ ¼ö ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´ ¿¹¹æ°ü¸®¼¾ÅÍ(CDC)¿¡ µû¸£¸é ¹é³»Àå, Ȳ¹Ýº¯¼º, ´ç´¢º´¸Á¸·Áõ, ³ì³»Àå µî ³ëÈ¿¡ µû¸¥ ¾ÈÁúȯÀÌ ¹Ì±¹¿¡¼ ½Ç¸í°ú ½Ã·ÂÀå¾ÖÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ´Ù¸¥ ÀϹÝÀûÀÎ ´« ÁúȯÀº ¾à½Ã¿Í »ç½Ã¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ¾È±¸°ÇÁ¶ÁõÀº 2030³â±îÁö 279¸¸¸íÀÇ ¹Ì±¹ ³²¼ºÀÌ º´À» ¾ÎÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼ ¾È±¸°ÇÁ¶ÁõÀÇ ÀÌȯÀ²ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ±¹³»¿¡¼´Â Ä¡·á¿ë Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. 2021³â 1¿ù, Kala Pharmaceuticals Inc.´Â ¾È±¸°ÇÁ¶Áõ Áõ»óÀÇ ´Ü±â(ÃÖ´ë 2ÁÖ) Ä¡·áÁ¦ EYSUVIS 0.25%(·ÎÅ×ÇÁ·¹µå³î ¿¡Å¸º¸³×ÀÌÆ® Á¡¾È¾×)¸¦ ¹ß¸ÅÇß½À´Ï´Ù. EYSUVIS´Â ÇöÀç ¹Ì±¹ ³» Àü±¹ ¹× Áö¿ª ÀǾàǰ À¯Åë ¼¾ÅÍ¿¡¼ ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù.
ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ¼öÀͰú 2031³â±îÁö ¿¹Ãø(±Ý¾×)
ºÏ¹Ì ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ¼¼ºÐÈ
ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº Á¦Ç°, º¹¿ë ÇüÅÂ, Á¦Ç° À¯Çü, À¯Åë ä³Î, ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.
Á¦Ç°¿¡ µû¶ó ºÏ¹Ì ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº Àΰø´«¹°, Ç׿°ÁõÁ¦, õÀÚ Ç÷¯±×, ºÐºñ ÃËÁøÁ¦, °æ±¸ ¿À¸Þ°¡ º¸ÃæÁ¦ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. Àΰø´«¹° ºÎ¹®Àº 2023³â ºÏ¹Ì ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ, Ç׿°ÁõÁ¦ ºÎ¹®Àº ½ÃŬ·Î½ºÆ÷¸°, ÄÚ¸£Æ¼ÄÚ ½ºÅ×·ÎÀÌµå µîÀ¸·Î ¼¼ºÐȵ˴ϴÙ. °Ô´Ù°¡, õÀÚ Ç÷¯±× ºÎ¹®Àº °¡¿ë¼º ¹× ºÐ¸®°¡´ÉÇÑ °ÍÀ¸·Î ¼¼ºÐȵ˴ϴÙ.
Á¦Çüº°·Î´Â ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº Á¡¾È¾à, °Ö, ĸ½¶ ¹× Á¤Á¦, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2023³â ºÏ¹Ì ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå Á¡À¯À²Àº Á¡¾È¾à ºÎ¹®ÀÌ °¡Àå ÄǽÀ´Ï´Ù.
Á¦Ç° À¯Çüº°·Î ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº ÀϹÝÀǾàǰ(OTC)°ú ó¹æÀüÀ¸·Î À̺е˴ϴÙ. 2023³â¿¡´Â ÀϹÝÀǾàǰ(OTC) ºÎ¹®ÀÌ ºÏ¹Ì ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå¿¡¼ ´õ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
À¯Åë ä³ÎÀ» ±â¹ÝÀ¸·Î ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº ¼Ò¸Å ¾à±¹, º´¿ø ¾à±¹, ¿Â¶óÀÎ ¾à±¹À¸·Î ºÐ·ùµË´Ï´Ù. ¼Ò¸Å ¾à±¹ ºÎ¹®Àº 2023³â ºÏ¹Ì ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. 2023³â ºÏ¹Ì ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå Á¡À¯À²Àº ¹Ì±¹ÀÌ µ¶Á¡Çß½À´Ï´Ù.
Santen Pharmaceutical Co Ltd, Johnson & Johnson, OASIS Medical, URSAPHARM Arzneimittel GmbH, Rohto Pharmaceutical Co Ltd, OCuSOFT Inc, Bausch Health Companies Inc, AbbVie Inc, Prestige Consumer Healthcare Inc.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
- Á¶»ç ¹üÀ§
- 2Â÷ Á¶»ç
- 1Â÷ Á¶»ç
Á¦4Àå ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ¾È±¸°ÇÁ¶ÁõÀÇ À¯º´·ü »ó½Â
- °í·ÉÀÚ Àα¸ Áõ°¡
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- Á¡¾È¾àÀÇ ºÎÀÛ¿ë°ú Á¦Ç° ȸ¼ö
- ½ÃÀå ±âȸ
- ÇâÈÄÀÇ µ¿Çâ
- ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ÀÇ Áö¼ÓÀû Á¶»ç¿Í ÆÄÀÌÇÁ¶óÀÎÀÇ ¼ºÀå
- ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ
Á¦5Àå ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå : ºÏ¹Ì ºÐ¼®
- ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ¼öÀÍ, 2021³â-2031³â
Á¦6Àå ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ºÐ¼® : Á¦Ç°º°
- Àΰø´«¹°
- Ç׿°ÁõÁ¦
- õÀÚ Ç÷¯±×
- ºÐºñ ÃËÁøÁ¦
- °æ±¸ ¿À¸Þ°¡ º¸ÃæÁ¦
- ±âŸ
Á¦7Àå ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ºÐ¼® : Á¦Çüº°
- Á¡¾È¾à
- Á©
- ĸ½¶ ¹× Á¤Á¦
- ±âŸ
Á¦8Àå ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ºÐ¼® : Á¦Ç° À¯Çüº°
Á¦9Àå ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ºÐ¼® : À¯Åë ä³Îº°
- ¼Ò¸Å ¾à±¹
- º´¿ø ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦10Àå ºÏ¹ÌÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå : ±¹°¡º° ºÐ¼®
Á¦11Àå ¾÷°è Á¤¼¼
- ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå¿¡¼ÀÇ ¼ºÀå Àü·«
- À¯±âÀû ¼ºÀå Àü·«
- ¹«±âÀû ¼ºÀå Àü·«
Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Santen Pharmaceutical Co Ltd
- Johnson & Johnson
- OASIS Medical
- URSAPHARM Arzneimittel GmbH
- Rohto Pharmaceutical Co Ltd
- OCuSOFT Inc.
- Bausch Health Companies Inc
- AbbVie Inc
- Prestige Consumer Healthcare Inc.
- Farmigea SpA
- Alcon AG
Á¦13Àå ºÎ·Ï
SHW
The North America dry eye products market was valued at US$ 3,825.36 million in 2023 and is expected to reach US$ 5,587.77 million by 2031; it is estimated to register a CAGR of 4.9% from 2023 to 2031.
Rising Prevalence of Dry Eye Fuels North America Dry Eye Products Market
Dry eye disease (DED) ranks third among the most common reasons for visits to an ophthalmology clinic after refractive errors and cataracts, respectively. The prevalence of dry eye is particularly rising in developed nations. Dry eye is caused by multiple factors that result in discomfort, irritation, and visual disturbance. According to an article published by the American Academy of Ophthalmology, DED affects approximately 1 in 11 people worldwide, with prevalence ranging from 5% to 50% at various ages. According to a press release by Alcon in 2022, the disease affects ~719 million people globally and ~38 million people in the US.
Progressive damage caused to the retina due to diabetic retinopathy further results in DED. According to an article published by the American Academy of Ophthalmology, ~191.0 million people globally are estimated to suffer from diabetic retinopathy by 2030. As per the Centers for Disease Control and Prevention (CDC), approximately 9.6 million people (across all ages) in the US were living with diabetic retinopathy in 2021. Thus, the increasing incidence of diabetic retinopathy is driving the growth of the dry eye products market.
North America Dry Eye Products Market Overview
The North America dry eye products market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the increasing awareness of dry eyes disease (DED), growing aging population, technological advancements, and rising eye disease cases. Moreover, an easy availability of various drugs due to frequent launches of new drugs is one of the key factors propelling the dry eye products market growth in the region.
DED is a common but underdiagnosed condition in the US, and an increase in the population age can be associated with the surging prevalence of this disease. According to the Centers for Disease Control and Prevention (CDC), age-related eye diseases such as cataract, macular degeneration, diabetic retinopathy, and glaucoma are the primary causes of blindness and impaired vision in the US. Other common eye disorders include amblyopia and strabismus. Dry eye disease is expected to affect as many as 2.79 million US men by 2030. Thus, with the rising incidence of dry eye disease, the demand for therapeutic products is on the rise in the country. In January 2021, Kala Pharmaceuticals Inc. launched EYSUVIS 0.25% (loteprednol etabonate ophthalmic suspension) for the short-term (up to two weeks) treatment of dry eye disease symptoms. EYSUVIS is now available in national and regional pharmaceutical distribution centers across the US.
North America Dry Eye Products Market Revenue and Forecast to 2031 (US$ Million)
North America Dry Eye Products Market Segmentation
The North America dry eye products market is categorized into product, dosage form, type, distribution channel, and country.
Based on product, the North America dry eye products market is segmented into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogues, oral omega supplements, and others. The artificial tears segment held the largest North America dry eye products market share in 2023. Furthermore, the anti-inflammatory drugs segment is subcategorized into cyclosporine, corticosteroid, and others. Additionally, the punctal plugs segment is subsegmented into dissolvable and removable.
In terms of dosage form, the North America dry eye products market is segmented into eye drops, gel, capsules and tablets, and others. The eye drops segment held the largest North America dry eye products market share in 2023.
By type, the North America dry eye products market is bifurcated into OTC and prescription. The OTC segment held a larger North America dry eye products market share in 2023.
Based on distribution channel, the North America dry eye products market is categorized into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment held the largest North America dry eye products market share in 2023.
By country, the North America dry eye products market is segmented into the US, Canada, and Mexico. The US dominated the North America dry eye products market share in 2023.
Santen Pharmaceutical Co Ltd, Johnson & Johnson, OASIS Medical, URSAPHARM Arzneimittel GmbH, Rohto Pharmaceutical Co Ltd, OCuSOFT Inc, Bausch Health Companies Inc, AbbVie Inc, Prestige Consumer Healthcare Inc, Farmigea SpA, and Alcon AG. are some of the leading companies operating in the North America dry eye products market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. North America Dry Eye Products Market - Key Market Dynamics
- 4.1 Market Drivers
- 4.1.1 Rising Prevalence of Dry Eye
- 4.1.2 Upsurge in Geriatric Population
- 4.2 Market Restraints
- 4.2.1 Side Effects of Eye Drops and Product Recalls
- 4.3 Market Opportunities
- 4.3.1 Increasing Initiatives for Eye Care Awareness
- 4.4 Future Trends
- 4.4.1 Ongoing Research and Growing Pipeline for Dry Eye Products
- 4.5 Impact of Drivers and Restraints:
5. Dry Eye Products Market - North America Analysis
- 5.1 North America Dry Eye Products Market Revenue (US$ Million), 2021-2031
6. North America Dry Eye Products Market Analysis - by Product
- 6.1 Overview
- 6.2 Artificial Tears
- 6.2.1 Overview
- 6.2.2 Artificial Tears: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 6.3 Anti-Inflammatory Drugs
- 6.3.1 Overview
- 6.3.2 Anti-Inflammatory Drugs: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 6.3.2.1 North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million) - by Anti-inflammatory Drugs
- 6.4 Punctal Plugs
- 6.4.1 Overview
- 6.4.2 Punctal Plugs: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 6.4.2.1 North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million) - by Punctal Plugs
- 6.5 Secretagogues
- 6.5.1 Overview
- 6.5.2 Secretagogues: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 6.6 Oral Omega Supplements
- 6.6.1 Overview
- 6.6.2 Oral Omega Supplements: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 6.7 Others
- 6.7.1 Overview
- 6.7.2 Others: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
7. North America Dry Eye Products Market Analysis - by Dosage Form
- 7.1 Overview
- 7.2 Eye Drops
- 7.2.1 Overview
- 7.2.2 Eye Drops: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 7.3 Gels
- 7.3.1 Overview
- 7.3.2 Gels: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 7.4 Capsules and Tablets
- 7.4.1 Overview
- 7.4.2 Capsules and Tablets: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
8. North America Dry Eye Products Market Analysis - by Type
- 8.1 Overview
- 8.2 OTC
- 8.2.1 Overview
- 8.2.2 OTC: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 8.3 Prescription
- 8.3.1 Overview
- 8.3.2 Prescription: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
9. North America Dry Eye Products Market Analysis - by Distribution Channel
- 9.1 Overview
- 9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 9.3 Hospital Pharmacies
- 9.3.1 Overview
- 9.3.2 Hospital Pharmacies: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 9.4 Online Pharmacies
- 9.4.1 Overview
- 9.4.2 Online Pharmacies: North America Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
10. North America Dry Eye Products Market - Country Analysis
- 10.1 North America: Dry Eye Products Market
- 10.1.1 North America: Dry Eye Products Market - Revenue and Forecast Analysis - by Country
- 10.1.1.1 United States: Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.1.1 United States: Dry Eye Products Market Breakdown, by Product
- 10.1.1.1.1.1 United States: Dry Eye Products Market Breakdown, by Anti-inflammatory Drugs
- 10.1.1.1.1.2 United States: Dry Eye Products Market Breakdown, by Punctal Plugs
- 10.1.1.1.2 United States: Dry Eye Products Market Breakdown, by Dosage Form
- 10.1.1.1.3 United States: Dry Eye Products Market Breakdown, by Type
- 10.1.1.1.4 United States: Dry Eye Products Market Breakdown, by Distribution Channel
- 10.1.1.2 Canada: Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.2.1 Overview
- 10.1.1.2.2 Canada: Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.2.3 Canada: Dry Eye Products Market Breakdown, by Product
- 10.1.1.2.3.1 Canada: Dry Eye Products Market Breakdown, by Anti-inflammatory Drugs
- 10.1.1.2.3.2 Canada: Dry Eye Products Market Breakdown, by Punctal Plugs
- 10.1.1.2.4 Canada: Dry Eye Products Market Breakdown, by Dosage Form
- 10.1.1.2.5 Canada: Dry Eye Products Market Breakdown, by Type
- 10.1.1.2.6 Canada: Dry Eye Products Market Breakdown, by Distribution Channel
- 10.1.1.3 Mexico: Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.3.1 Overview
- 10.1.1.3.2 Mexico: Dry Eye Products Market - Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.3.3 Mexico: Dry Eye Products Market Breakdown, by Product
- 10.1.1.3.3.1 Mexico: Dry Eye Products Market Breakdown, by Anti-inflammatory Drugs
- 10.1.1.3.3.2 Mexico: Dry Eye Products Market Breakdown, by Punctal Plugs
- 10.1.1.3.4 Mexico: Dry Eye Products Market Breakdown, by Dosage Form
- 10.1.1.3.5 Mexico: Dry Eye Products Market Breakdown, by Type
- 10.1.1.3.6 Mexico: Dry Eye Products Market Breakdown, by Distribution Channel
11. Industry Landscape
- 11.1 Overview
- 11.2 Growth Strategies in the Dry Eye Products Market
- 11.3 Organic Growth Strategies
- 11.4 Inorganic Growth Strategies
12. Company Profiles
- 12.1 Santen Pharmaceutical Co Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Johnson & Johnson
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 OASIS Medical
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 URSAPHARM Arzneimittel GmbH
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Rohto Pharmaceutical Co Ltd
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 OCuSOFT Inc.
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Bausch Health Companies Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 AbbVie Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 Prestige Consumer Healthcare Inc.
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 Farmigea SpA
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
- 12.11 Alcon AG
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments
13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms